Bluestar Adisseo Co. Class A

Bluestar Adisseo Co. Class A

SSSE:600299
8.16
CNY
-0.04
(-0.49%)
0.61EPS
13.38P/E
25.28BMarket Cap
Mar 26Next Earn
Bluestar Adisseo Co. Class A
SSE:600299
(Shanghai Stock Exchange)

Recent

price

8.16

P/E

ratio

13.38

div

yld

2.20%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
17.95
22.29
17.39
15.82
7.39
5.76
4.01
3.85
4.32
4.15
4.41
4.81
5.36
5.05
5.8
6.42
6.56
Revenue per Share
0.14
0.14
-1.99
-2.18
0.56
0.58
0.7
0.49
0.35
0.37
0.5
0.55
0.46
0.02
0.45
0.43
0.61
Basic EPS, GAAP
-3.15
-4.47
-1.05
-0.83
0.38
0.97
0.92
0.57
0.07
0.49
0.51
0.11
0.07
0.5
0.49
-0.14
- -
Free Cash Flow per Basic Share
0.47
0.64
1.54
1.53
0.44
0.17
0.15
0.23
0.18
0.29
0.16
0.19
0.2
0.2
0.11
0.22
0.18
Dividend per Share
5.49
5.64
3.63
1.46
14.61
3.8
4.5
4.91
5.07
5.14
5.2
5.26
5.57
5.61
5.8
6.45
6.58
Book Value per Share
3.64
3.89
1.97
-0.16
7.35
2.72
3.46
3.89
3.58
3.71
3.64
3.73
4.05
3.95
4.21
5.01
5.26
Tangible Book Value per Share
539
511
522
522
2,635
2,636
2,665
2,701
2,646
2,682
2,703
2,676
2,710
2,608
2,676
2,685
2,984
Basic Weighted Avg Shares
9,676
11,395
9,084
8,263
19,465
15,173
10,688
10,398
11,418
11,135
11,910
12,869
14,529
13,184
15,534
17,231
19,581
Sales/Revenue/Turnover
3.6
1.84
-6.66
-7.88
8.64
27.76
29.99
21.71
15.33
13.59
18.23
16.78
12.04
2.91
12.55
11.88
14.68
Operating Margin (%)
464
493
556
502
1,504
1,145
839
810
947
977
1,117
1,178
1,321
1,707
1,573
1,573
- -
Depreciation Expense
75
72
-1,039
-1,139
1,475
1,529
1,865
1,323
926
992
1,352
1,472
1,247
52
1,204
1,155
1,831
Net Income, GAAP
41.25
39.49
- -
- -
26.43
44.76
27.37
29.79
27.5
27.4
26.07
25.04
18.89
18.25
23.44
26.35
24.68
Effective Tax Rate (%)
0.78
0.63
-11.44
-13.78
7.58
10.07
17.45
12.73
8.11
8.91
11.35
11.44
8.58
0.4
7.75
6.7
9.35
Profit Margin (%)
-3,846
-4,823
-6,453
-9,094
-7,008
6,140
7,856
8,364
6,842
6,524
2,940
2,457
2,293
1,823
2,519
4,808
6,311
Working Capital
2,546
3,349
4,225
3,260
3,126
16
14
13
31
26
234
156
1,125
1,063
1,240
1,897
2,331
LT Debt
3,049
3,112
2,025
900
11,272
14,182
15,887
17,257
17,398
17,215
15,432
15,426
14,953
15,065
15,570
19,896
20,309
Total Equity
0.42
-1.21
- -
- -
9.76
10.91
14.98
9.85
6.85
6.54
8.79
9.23
7.17
0.32
7.61
6.19
- -
Return on Invested Capital (%)
2.59
2.53
- -
- -
10.62
6.74
9.39
5.84
3.66
4.22
7.28
8.6
7.59
0.76
7.34
6.02
- -
Return on Capital (%)
2.67
2.46
-42.89
-85.49
35.13
17.15
16.76
10.49
6.92
7.24
9.74
10.49
8.59
0.35
7.88
6.52
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
564
483
505
LT Borrowings
1,829
1,909
2,091
LT Finance Leases
254
251
240
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
3,080
3,080
3,080
Market Capitalization
40,130
24,176
25,285

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
9,780
10,558
11,134
Cash, Cash Equivalents & STI
4,507
4,441
4,578
Accounts Receivable, Net
2,008
2,319
2,387
Inventories
2,440
2,801
3,078
Total Current Liabilities
4,785
5,130
4,823
Payables & Accruals
- -
- -
- -
ST Debt
564
483
505
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.88%
5.76%
27.79%
Free Cash Flow
87.77%
72.76%
-128.12%
Net Income, GAAP
210.86%
420.46%
-4.13%
Sales/Revenue/Turnover
2.25%
8.09%
10.92%
Total Cash Common Dividend
11.79%
15.48%
105.21%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,496
3,765
4,115
4,158
15,534
2025
4,299
4,213
- -
4,300
17,231
2026
4,403
5,304
5,574
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.1
0.12
0.15
0.07
0.45
2025
0.17
0.1
- -
0.06
0.43
2026
0.1
0.19
0.25
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.07
0.01
0.11
2025
0.07
0.13
- -
0.01
0.22
2026
0.06
0.01
0.1
- -
- -
Business
Bluestar Adisseo Company (600299.SS), a leading global provider of animal nutrition solutions, engages in the research, development, production and sale of feed additives including methionine (powder and liquid forms such as Rhodimet AT and Rhodimet Nutrition), vitamins (notably vitamin A and vitamin E), enzymes, probiotics, organic selenium, amino acids (lysine, threonine, tryptophan), mycotoxin management products (Unike Plus, Toxy-Nil), antioxidants (Oxy-Nil), specialties for aquaculture (Aqualyso, Lipogest, Sanacore GM, Bacti-Nil Aqua, Apex Branchia), ruminants (Smartamine, Selisseo), swine and poultry; it also offers services such as PNE, Nestor, Asict, DIM, E.Lab and MycoMan. Founded in 1939 in France and headquartered in Beijing, China, the company operates through strategic business units in methionine, vitamins and specialties, serving over 4,200 customers in more than 110 countries across Europe, Asia, North America, the United States and Thailand with 17 production sites and 6 research centers. As a main subsidiary of China National Bluestar (Group) Co., Ltd., Bluestar Adisseo focuses on livestock, aquaculture, swine, ruminants, poultry and pet food sectors with tailored nutritional solutions emphasizing sustainability, animal health and performance. Recent developments include strong Q1 2025 revenue growth of 23% to CNY4.3 billion driven by methionine (+29%) and specialties (+7%), alongside a 67.9% increase in net profit to CNY465 million; H1 2025 net profit rose 22% to CNY740 million with revenue up 17% to CNY8.51 billion, supported by volume growth in liquid methionine (+16%), vitamins and specialties (ruminants +29% via Smartamine, Norfeed +18%). Key projects advancing comprise the 150KT powder methionine plant in Quanzhou (construction on track with sulfuric acid project started), European liquid methionine capacity expansion (full operations by end-2025), 37KT Nanjing specialties blending facility (licensed early 2025 with first sales in March), 30KT European specialties optimization (fully operational), Nanjing wastewater treatment (June 2025 commissioning), new acidifiers for China, FeedKind commercialization in aqua and pet markets, and a private placement refinancing of up to CNY3 billion accepted by the Shanghai Stock Exchange in April 2025 with dividends totaling over 40% payout ratio distributed in March and May.